Linux 是一种自由和开放源码的类 UNIX 操作系统，英文解释为 Linux is not Unix 。Linux 是在 1991 由林纳斯·托瓦兹在赫尔辛基大学上学时创立的，主要 受到 Minix 和 Unix 思想的启发。 根据 GNU 通用公共许可证（GPL），任何人都可以自由地使用 Linux 的原始源代码，同时有权对其进行修改和重新分发，只要他们同样遵循 GPL 的条 款。 Linux Mint 是一个基于 Ubuntu 的 Linux 发行版，以其易用性和美观的用户 界面而受到广泛欢迎。 大多数人都是直接使用 Linux 发行版，而不是自己选择每一样组件或自行设置。 如果是刚入门的新手首推：Ubuntu & Linux Mint 1、Ubuntu Ubuntu 多年来一直是最受欢迎的 Linux 发行版之一，凭借稳定的长期支持版本（LTS）、庞大的社区生态和良好的兼容性，在桌面和服务器领域均有极高 的占有率。 适合人群： 新手用户、开发者、企业用户 关键词： 稳定、易用、社区活跃、LTS 支持 2025 年发布的 Ubuntu 24.04 LTS 更是进一步优化了性能和安全性，继续成为默认首选 ...

Financial Data and Key Metrics Changes - The company is focused on minimizing dilution and maintaining a clean cap table, having renewed a $12 million line of credit and funding the business through selective capital raises [27] - The company aims to keep clinical trial costs low, achieving approximately half the typical cost per patient for Phase II trials, which usually range from $100,000 to $150,000 [28] Business Line Data and Key Metrics Changes - The lead asset, IGC-81, is in a Phase II trial for agitation in Alzheimer's dementia, with 146 participants currently enrolled across 22 sites [9][10] - The company has made significant progress on the CALMA trial, adding several new sites and utilizing geo-targeting strategies to enhance patient recruitment [5][12] Market Data and Key Metrics Changes - Agitation affects about 76% of Alzheimer's patients, with approximately 50 million Alzheimer's patients worldwide, including 7 million in the US [7] - The current market for Alzheimer's treatments includes cognitive enhancers and recently approved disease-modifying therapies, with IGC-81 positioned as a potential alternative [32][33] Company Strategy and Development Direction - The company is advancing its AI platform for early detection of Alzheimer's and has developed a new diagnostic model called MINT AD [20][23] - The strategy includes expanding the pipeline into GLP-1 based therapies, targeting both Alzheimer's and metabolic disorders, which could open up a multibillion-dollar market [26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the trial's progress and the potential for IGC-81 to serve as a disease-modifying therapy, which could significantly enhance the company's valuation [70][71] - The focus is on completing the Phase II trial and launching IGC-81 as a disease-modifying therapy, with positive results expected to drive higher valuations [69][70] Other Important Information - The company has been recognized by the NIH for innovation and is a finalist in the NIA Prepare Challenge for early Alzheimer's detection [24] - The AI model MINT AD aims to identify high-risk groups for Alzheimer's and predict cognitive decline, which could serve as a valuable tool for general practitioners [21][23] Q&A Session Summary Question: Insight into the competitive landscape for Alzheimer's drugs - Management highlighted that current treatments primarily include cognitive enhancers and recently approved disease-modifying therapies, with IGC-81 positioned as a differentiated oral therapy [32][33] Question: Adequacy of trial sites for current trials - Management confirmed that they have 22 sites and are using geo-targeting strategies to increase patient enrollment by approximately 200% [36] Question: Impact of social media on clinical trial costs - Management indicated that the cost of using social media for recruitment would be marginal, budgeting about $1,000 per recruited patient [41][42] Question: Timeline for CALMA trial completion - Management expects to finish the CALMA trial by March of next year, with ongoing discussions for future trials related to amyloid and tau [50][52] Question: Concerns regarding ARIA with current therapies - Management stated that IGC-81 is not a monoclonal antibody and does not expect ARIA, emphasizing its safety profile [56] Question: Positioning against traditional cannabis use - Management clarified that IGC-81 is a medication with controlled dosing and replicability, differentiating it from recreational cannabis [58][60] Question: Expectations for G&A expenses going forward - Management noted a refocus on key priorities, which has led to a reduction in G&A expenses, aiming to complete trials efficiently [63][66]

Financial Data and Key Metrics Changes - The company is focused on minimizing dilution and maintaining a clean cap table, having renewed a $12 million line of credit and funding through selective capital raises [26] - The cost per patient in Phase II trials is significantly lower than industry standards, with the company managing to conduct trials at about half the typical cost of $100,000 to $150,000 per patient [27] Business Line Data and Key Metrics Changes - The lead asset, IGC-81, is in a Phase II trial for agitation in Alzheimer's dementia, with 146 participants currently enrolled across 22 sites [9][10] - The company has made significant progress on the CALMA trial, adding several new sites and utilizing geo-targeting strategies to increase patient recruitment by about 200% [12][36] Market Data and Key Metrics Changes - Agitation affects approximately 76% of Alzheimer's patients, with around 50 million Alzheimer's patients worldwide and about 7 million in the U.S. [7] - The current Alzheimer's treatment landscape includes cognitive enhancers and recently approved disease-modifying therapies, but challenges remain regarding cost and eligibility [32] Company Strategy and Development Direction - The company is advancing its pipeline into the GLP-1 portfolio, which could target a multibillion-dollar market for metabolic disorders [25] - The focus is on completing the Phase II trial for IGC-81 and launching it as a disease-modifying therapy, with plans to initiate IND enabling studies for pipeline expansion [28][29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the trial's progress and the potential for IGC-81 to serve as a complementary or alternative solution in the symptomatic management of Alzheimer's [35] - The company is excited about the MINT AD AI model, which aims to help diagnose Alzheimer's risk factors and predict cognitive decline [22][64] Other Important Information - The company has been recognized by the NIH for innovation and was selected as a top finalist in the NIA Prepare Challenge for early Alzheimer's detection [23] - The beta version of the MINT AD model is operational and aims to assist general practitioners in diagnosing Alzheimer's [22] Q&A Session Summary Question: Insight into the competitive landscape - The current Alzheimer's treatment landscape includes cognitive enhancers and recently approved disease-modifying therapies, with IGC-81 positioned as a differentiated oral investigational therapy [32][34] Question: Adequacy of trial sites - The company currently has 22 sites and is using geo-targeting strategies to increase enrollment, projecting to meet enrollment targets without needing additional sites [36][37] Question: Cost implications of using social media for recruitment - The budget for recruiting new patients via social media is approximately $1,000 per patient, which will not significantly increase overall trial costs [41] Question: Timeline for CALMA trial top line results - The CALMA trial is expected to finish by March of next year, with the company internally aiming for a more aggressive timeline [49] Question: Concerns about ARIA with the drug - The medication is not a monoclonal antibody, so the company does not expect ARIA and has not seen any indications of it [55] Question: Positioning against traditional cannabis - The drug is a combination medication with controlled dosing, differentiating it from traditional cannabis use [57][60] Question: Future expectations for G&A expenses - The company has refocused on key priorities, which has led to a reduction in G&A expenses, aiming to complete trials and develop the MINT AD model [62][65]

Group 1 - Company Meituan has been ranked 208th in the 2025 Fortune Southeast Asia 500 list, which highlights the highest revenue companies in Southeast Asia, reflecting strong financial performance in 2024 [1] - In 2024, Meituan achieved a total revenue of $1.51 billion, representing a year-on-year growth of 43.0%, with gross profit reaching $316.3 million, up 45.6% [1] - The adjusted EBITDA for 2024 was $138.3 million, marking a growth of 31.3% [1] Group 2 - The core driver of growth for Meituan is its continuous investment in AI and machine learning, with its programmatic interactive advertising platform Mintegral being a key growth engine [1] - Mintegral generated $1.44 billion in revenue in 2024, a 47.2% increase year-on-year, with smart bidding products contributing over 70% of total revenue [1] - The diversified vertical strategy has shown significant results, with Mintegral's gaming business revenue reaching $1.04 billion, a growth of 37.0%, while non-gaming revenue surged by 82.0% to $403.3 million [1][2] Group 3 - The CEO of Meituan emphasized the company's focus on transforming complex problems into growth opportunities in the rapidly evolving AI and advertising technology landscape [2] - The Fortune Southeast Asia 500 list showcases the economic vitality of the region, with the 500 companies generating a total revenue of $1.82 trillion [2]

Beta Bionics (BBNX) Update / Briefing June 22, 2025 08:00 AM ET Speaker0 All right. Thanks everyone for joining us today for our first investor and analyst event. Sorry for the technical difficulties and brief delay, but we're up and running now. But yes, appreciate everyone joining on an early Sunday morning. By way of quick introduction, I'm Blake Bieber, Head of Investor Relations at Beta Bionics. We have a great agenda for you today. I'm joined here by Sean Sain, our CEO Mike Menseneger, our Chief Produ ...

MINT-CoT团队 投稿 量子位 | 公众号 QbitAI 思维链（Chain of Thought, CoT）推理方法已被证明能够显著提升大语言模型（LLMs）在复杂任务中的表现。而在多模态大语言模型 （MLLMs）中，CoT 同样展现出了巨大潜力。 3. 过度依赖外部功能 像 MVoT 或 Visual SKETCHPAD 等方法，需要借助外部工具或能力来生成或修改图像，训练和推理过程成本高、不通用。 然而，当视觉信息与数学推理结合时，传统的 CoT 方法就显得力不从心了——视觉输入中的数学细节往往被忽略，导致推理结果不准确。 最近，香港中文大学 MMLab 团队正式发布了全新的视觉推理方案——MINT-CoT，专为解决"多模态数学推理"中的难题而设计。 为什么数学视觉推理这么难？ 尽管已有一些研究尝试把视觉信息引入 CoT 推理，例如 Visual-CoT、Visual SKETCHPAD、VPT、ICoT 等方法，但在数学场景下依然存 在 三大瓶颈： 1. 粗粒度图像区域选择 大部分方法依赖边界框（Bounding Box）来截取图像区域。但数学图像里的元素（比如坐标轴、几何图形、标注文字等）高度关 ...

业 及 产 业 计算机 2025 年 06 月 07 日 Circle 美股上市需求火爆！EDA 国 行 业 研 究 / 行 业 点 评 相关研究 《EDA 加强对华管制！香港发布《稳定币 条例》——计算机行业周报 20250526- 20250530》 2025/06/02 《Robotaxi 盈利弹性来源！AI 产业三大进 展—— 计算机行业周报 20250519- 20250523 》 2025/05/24 证券分析师 黄忠煌 A0230519110001 huangzh@swsresearch.com 洪依真 A0230519060003 hongyz@swsresearch.com 胡雪飞 A0230522120002 huxf@swsresearch.com 刘洋 A0230513050006 liuyang2@swsresearch.com 研究支持 崔航 A0230524080005 cuihang@swsresearch.com 徐平平 A0230123060004 xupp@swsresearch.com 曹峥 A0230525040002 caozheng@swsresearch.com ...

Core Insights - The company, 汇量科技, reported strong financial performance for the three months ending March 31, 2025, with a significant revenue increase and enhanced profitability [1] - The Mintegral platform's revenue reached $420.8 million, reflecting a year-on-year growth of 48.4% [1] - Net profit for the company was $19.882 million, showing a remarkable year-on-year increase of 177.9% [1] Revenue Breakdown - The intelligent bidding products, including Target ROAS, contributed over 80% of Mintegral's total revenue, highlighting their role as a key growth driver [1] - The gaming category on the Mintegral platform generated $30.57 million in revenue, marking a substantial year-on-year growth of 50.7% [2] - Non-gaming categories also performed well, with revenue of $11.51 million, representing a year-on-year increase of 42.5% [2] Strategic Developments - The company has made significant investments in AI and machine learning for its bidding systems, which have been well-received by advertisers [1] - The optimization of advertising budget structures and a more balanced business layout have been achieved through the continuous enhancement of Mintegral's intelligent bidding capabilities [2]

Company Overview - Monarch, a personal finance startup, has raised $75 million to enhance subscriber growth following the shutdown of budgeting tool Mint [1] - The company is valued at $850 million after this funding round, which is one of the largest for an American consumer fintech startup this year [1] Product and Market Position - Monarch aims to provide an all-in-one mobile app for tracking spending, investments, and financial goals, filling the gap left by Mint [2] - The personal finance management space has seen limited innovation since the late 90s, with Monarch seeking to modernize how American families manage their finances [3] Subscriber Growth - Following the announcement of Mint's closure, Monarch experienced a 20-fold increase in its subscriber base as users looked for alternatives [3] - Unlike Mint, which was free, Monarch operates on a subscription model, allowing it to avoid reliance on advertising and data sales [4]

阜博集团(03738)：公司2024年收入同增20%至24亿港元，2024年毛利同增24%至11亿港元，毛利率同增 1.3pct至43.8%；经调整净利润同增380%至1.8亿港元。收入增长主要得益于美国业务的持续扩张、战略 及商业合作推动的中国内地业务扩展。净利润的显著改善则得益于毛利率的提升和运营效率的优化。 通信与互联网行业分析师马继华表示，在全球范围内，由于美国AI政策多变且不透明，许多国家不再 依赖其基础设施，而是加快自主AI体系建设。 5月22日，在2025阿里云中企出海大会上，阿里巴巴集团CEO、阿里云智能集团董事长兼CEO吴泳铭表 示，阿里云将以战略级投入，加速打造全球云计算一张网，加速AI产品国际化，增强出海咨询、技术 和服务团队建设，为中国企业出海铺路搭桥。 营收在欧美的港股AI企业： 汇量科技(01860)：2024年以来，广告市场持续回暖，使得公司业务保持强劲增长，24Q3实现营收4.16 亿美元，同比增加54.6%，其中贡献主要收入的程序化广告平台Mintegral录得收入4.02亿美元，同比增 长57.6%。2024年7月Mintegral推出针对事件进行投放优化的Target-C ...